Your browser doesn't support javascript.
loading
Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya, Naoki; Miyazaki, Taiga; Fukushige, Yuri; Takemori, Sachiko; Morimoto, Shinpei; Yamamoto, Hiroshi; Hori, Makoto; Kurokawa, Tomoya; Kawasaki, Yohei; Hanawa, Michiko; Fujii, Yasuhisa; Hanaoka, Hideki; Iwami, Shingo; Watashi, Koichi; Yamagoe, Satoshi; Miyazaki, Yoshitsugu; Wakita, Takaji; Izumikawa, Koichi; Yanagihara, Katsunori; Mukae, Hiroshi; Kohno, Shigeru.
Afiliación
  • Hosogaya N; Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Miyazaki T; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Fukushige Y; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan. taiga-m@nagasaki-u.ac.jp.
  • Takemori S; Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. taiga-m@nagasaki-u.ac.jp.
  • Morimoto S; Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Yamamoto H; Department of Hospital Pharmacy Nagasaki University Hospital, Nagasaki, Japan.
  • Hori M; Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Kurokawa T; Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Kawasaki Y; Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Hanawa M; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Fujii Y; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Hanaoka H; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Iwami S; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Watashi K; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Yamagoe S; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Miyazaki Y; Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan.
  • Wakita T; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • Izumikawa K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Yanagihara K; Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
  • Mukae H; Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kohno S; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Trials ; 22(1): 309, 2021 Apr 28.
Article en En | MEDLINE | ID: mdl-33910617
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male / Middle aged / Pregnancy País/Región como asunto: Asia Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male / Middle aged / Pregnancy País/Región como asunto: Asia Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Japón